Sol-Gel Technologies (SLGL) has released an update.
Sol-Gel Technologies, a dermatology company known for its innovative skin treatments and FDA-approved products, has announced a management shake-up. CEO Dr. Alon Seri-Levy will step down by the end of 2024 and transition to a consulting role, while Eyal Ben-Or ascends to the CFO position, bringing extensive financial experience to the company. These changes come as the company continues to progress with its promising product pipeline, including a Phase 3 clinical trial for Gorlin syndrome.
For further insights into SLGL stock, check out TipRanks’ Stock Analysis page.
